Target validation and engagement

Understanding a drug’s primary target is crucial for successful development. However, inadequate validation of targets early on can lead to costly clinical failures. At Inoviem Scientific we help you overcome these challenges by: 

• Validating targets in your chosen model: Whether cell line, primary cells, iPSCs, or animal models, we can validate candidate targets within the same model you’re using for further development. 
• Dose-dependency target engagement studies as proof of concept: with our LIPS ® Platform we show how your molecule is interacting, dose dependently, with its therapeutic targets in living models
• Unveiling the full interactome: when not sure of therapeutic target or suspecting off-target interactions, our proteomic platform combined with NPOT® technology allows for comprehensive analysis. This technology reveals the complete protein network your compound interacts with, including both beneficial (on-targets) and unintended interactions (off-targets). Importantly, it preserves the natural structure and conformation of these proteins. Through pathway enrichment analysis, we can identify and validate both on- and off-targets, leading to a deeper understanding of potential toxicity pathways.